Shifting the Evolving CAR T Cell Platform into Higher Gear
Menée in vitro et in vivo, cette étude met en évidence l'activité antitumorale d'une nouvelle génération de lymphocytes T modifiés pour exprimer un récepteur d'antigène chimérique (4-1BBL)
In this issue of Cancer Cell, Zhao and colleagues test various chimeric antigen receptor (CAR) T cells to show that CD28-CD3
ζ CAR T cells that constitutively express 4-1BBL promote T cell expansion and tumor eradication while reducing exhaustion. The results have important implications for the development of effective CAR T cell therapies in cancer patients.
Cancer Cell , commentaire, 2014